A recent study found that weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduced the risk of a combination of stroke, heart attack, and death from cardiovascular causes by 20% compared with placebo. A primary cardiovascular event occurred in 6.5% of the semaglutide group and 8% of the placebo group.
